Can extra support improve end-of-life care for blood cancer patients?
NCT ID NCT03310918
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 18 times
Summary
This study looks at whether adding a palliative care team to standard leukemia treatment helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life care. About 320 patients receiving non-intensive therapy will take part. The goal is to improve quality of life, mood, and how early patients discuss their care wishes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.